Please login to the form below

Not currently logged in
Email:
Password:

Novartis Oncology head Bruno Strigini to retire

Will leave the Swiss pharma firm, and the industry, next year

Novartis Bruno StriginiThe head of Novartis Oncology Bruno Strigini is set to step down and retire from the pharmaceutical industry.

Citing personal reasons, the Swiss pharma firm said Strigini would step back from his place on its executive committee by December 31 and leave his current role in early 2018.

Novartis CEO Joseph Jimenez said: "I'd like to thank Bruno Strigini for his contributions and achievements. He has navigated the business unit through the Gleevec patent expiration and has led the successful integration of the GSK Oncology Product Portfolio acquired in 2015. I wish him the best for his future."

Strigini joined Novartis in 2014 from Merck & Co, where he spent nearly five years as president, Europe and Canada.

Prior to that he served in a similar role at Schering-Plough, before its acquisition by Merck in 2009.

19th December 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics